MHRAsafety guidance54% confidence
Policy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goals
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as Bayer.
Regulatory Analysis
Goals agreed with the Medicines and Healthcare products Regulatory Agency to clarify how their actions should support economic growth.
Supporting Context
- Therapeutic area
- Cardiology · Pulmonary Hypertension
- Sub-indication
- Hypertension
Related signal: FDA Accepts Supplement for ADEMPAS (Riociguat) by Bayer Healthcare